| Released | Contributor | Author | Title | Pages | Price |
| 24-Dec-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 24-Dec-2009 | New Constructs, LLC |
N/A
| CLDX: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 24-Dec-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 23-Dec-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for BIOTECHNOLOGY | 18 |
$49 |
| 21-Dec-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for CLDX | 13 |
$25 |
| 19-Dec-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: CELLDEX THERAPEUTICS INC | 5 |
$25 |
| 19-Dec-2009 | Standard & Poor's Factual Report |
N/A
| Celldex Therapeutics | 7 |
$35 |
| 17-Dec-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: CELLDEX THERAPEU -- CLDX | 1 |
$4 |
| 17-Dec-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: AVGN , CLDX , CRIS , FACT , LJPC , PPHM , VION -- DRUGS | 3 |
$4 |
| 17-Dec-2009 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of CELLDEX THERAPEUTICS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 3 |
$20 |
0.51% Nasdaq 
Research Reports
